<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1FFD79A0-0681-4141-A504-FDE130EF7F33"><gtr:id>1FFD79A0-0681-4141-A504-FDE130EF7F33</gtr:id><gtr:firstName>Mahesh</gtr:firstName><gtr:surname>Parmar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12023%2F9"><gtr:id>C15EC379-686B-4C44-92D6-B976E6499016</gtr:id><gtr:title>Clinical Trials in Gynaecological Cancer.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12023/9</gtr:grantReference><gtr:abstractText>Ovarian cancer is the fourth most common cause of cancer-related death in women. Research at the MRC CTU aims to improve outcomes for women with ovarian cancer, who in spite of a good response to initial treatment, often develop recurrent disease and die. The OV05 trial showed that women treated for recurrence when their CA125 rose did not live longer or have better quality of life than women treated later when they had symptoms or signs of recurrence. |Ovarian cancer treatment includes surgery and chemotherapy. Outcomes (including quality of life) may be improved by giving chemotherapy before and after surgery, making surgery easier with more tumour removed. This is being investigated in the CHORUS trial. |Drugs which block growth factors that ovarian cancer cells need to grow and spread are being tested in randomised trials including bevacizumab (ICON7), erlotinib (Ov07), and cediranib (ICON6). Linked laboratory studies are investigating whether it is possible to predict who will respond to treatments. |It may be possible to improve outcomes in women with newly diagnosed ovarian cancer by giving standard chemotherapy as weekly treatments rather than 3 weekly. This will be investigated in the recently funded ICON8 trial.</gtr:abstractText><gtr:technicalSummary>Epithelial ovarian carcinoma (EOC) is the fourth most common cause of cancer-related death in women and the most lethal gynaecological malignancy. Although it responds well to initial chemotherapy (response rates &amp;gt; 70%) the majority of women (even those who achieve a complete remission) ultimately develop recurrent disease and die. Median progression free survival (PFS) for patients with advanced disease ranges between 16 and 21 months while the median overall survival (OS) lies between 31 and 57 months.||Early treatment of relapse based on the blood biomarker CA125 was evaluated in the OV05 trial. First results, presented at the ASCO in 2009 suggested that starting chemotherapy early based on CA125 alone compared to waiting to start chemotherapy when symptoms occur, does not improve overall survival or quality of life. A manuscript for publication is currently under review.||New treatment strategies based on the fact that ovarian tumours are associated with high expression of angiogenic factors including vascular endothelial growth factor (VEGF) and endothelial growth factor (EGF) have been developed. These factors are targets for newer drugs which block growth factors or their receptors including bevacizumab (ICON7), erltotinib (OV07) and cediranib (ICON6). First results of ICON7 will be presented in 2010. The standard treatment of newly diagnosed ovarian carcinoma includes primary surgery with removal of as much of the tumour as possible (optimal debulking) followed by platinum-based chemotherapy. Some chemotherapy before and after surgery (neoadjuvant chemotherapy) is an alternative treatment strategy being investigated in the CHORUS trial. Optimal debulking may be easier to achieve after 3 cycles of chemotherapy and reduced post operative morbidity could improve quality of life. |Giving standard chemotherapy with carboplatin and paclitaxel as weekly treatments rather than 3 weekly may lead to improved progression free and overall survival in women with newly diagnosed ovarian cancer. This will be investigated in the recently funded ICON8 trial.||ICON3 results, published in 2001 were controversial. OS and PFS were no better in patients treated with platinum based chemotherapy plus paclitaxel than in patients treated with platinum based chemotherapy alone. The ICON3 p53 study investigates the role of the p53 gene in response to platinum. There is evidence to support the hypothesis that patients with wild type p53 have high response rates to single agent carboplatin and may gain no benefit from the addition of paclitaxel chemotherapy. This may explain the result of ICON3 and ICON4. Results will be available in 2011.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1376000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with AstraZeneca on cedaranib following ICON6 trial outcome</gtr:description><gtr:id>B3D47E3F-9D9D-4534-A1C1-942128104D65</gtr:id><gtr:impact>Full study report in development</gtr:impact><gtr:outcomeId>546200ac855937.54748239-1</gtr:outcomeId><gtr:partnerContribution>Drug supply only until positive outcome of the study was reported. Subsequently, close colloaboration on preparation of regulatory package.</gtr:partnerContribution><gtr:piContribution>Sponsored and ran the ICON6 trial after AZ abandoned development of this compound. Now working with them to produce licensing application. Anticipate considerable research support plus drug supply for trials to follow.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E6347B31-885A-44AB-8078-19F62232C597</gtr:id><gtr:title>Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f6641b4ea0e8a2a49263c1e6f53f86d"><gtr:id>9f6641b4ea0e8a2a49263c1e6f53f86d</gtr:id><gtr:otherNames>Kommoss S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>58b98afcd2c1c6.69547993</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C1D0BB2-4659-4767-BB93-FB23BA2B7335</gtr:id><gtr:title>Outcomes and endpoints in cancer trials: bridging the divide.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/477b885db33d0da24a7c79afa28589e7"><gtr:id>477b885db33d0da24a7c79afa28589e7</gtr:id><gtr:otherNames>Wilson MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>56e022f19b5805.28627736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2245015-3714-4516-A566-328AB6BD3CBE</gtr:id><gtr:title>Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).</gtr:title><gtr:parentPublicationTitle>BMC public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51e69440a03316ac5cb33099510f4fcb"><gtr:id>51e69440a03316ac5cb33099510f4fcb</gtr:id><gtr:otherNames>Bailey K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2458</gtr:issn><gtr:outcomeId>56e022f10b2fe6.41199780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC12E851-EEAB-41B8-BFBA-396D4144B5AD</gtr:id><gtr:title>Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/593393822da26709697a3e72eafc6de5"><gtr:id>593393822da26709697a3e72eafc6de5</gtr:id><gtr:otherNames>Stark DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>5a9aa639c99e09.74193633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E1186FC-D452-4E6A-9F7D-5BEBC5CC3D90</gtr:id><gtr:title>Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9098f85cfb4aaf62ae766b74b6b220c2"><gtr:id>9098f85cfb4aaf62ae766b74b6b220c2</gtr:id><gtr:otherNames>Kehoe S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56e022eff1fa96.04424792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5617450B-903B-4EBB-897E-C541E6DEF71D</gtr:id><gtr:title>Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee6d6da88c36581a49a125d8c642532e"><gtr:id>ee6d6da88c36581a49a125d8c642532e</gtr:id><gtr:otherNames>Ledermann J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b990783c9803.44220746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C4CBF90-56AA-4950-8349-F39A10914B3E</gtr:id><gtr:title>Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e76a8a0d73090fe4ee75ba8038539c8"><gtr:id>0e76a8a0d73090fe4ee75ba8038539c8</gtr:id><gtr:otherNames>Zhou C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58b98ec51b6ff0.34229672</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12023/9</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>